Joseph Goldstein L.'s most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 1,958 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,958 | 1,958 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 166 | 6,548 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | L. Joseph Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 625.60 per share. | 23 Jan 2024 | 2,707 | 9,089 (0%) | 0% | 625.6 | 1,693,499 | Common Stock |
| Regeneron Pharma | Joseph Goldstein L. | Director | Sale of securities on an exchange or to another person at price $ 950.00 per share. | 23 Jan 2024 | 2,707 | 6,382 (0%) | 0% | 950 | 2,571,650 | Common Stock |
| Regeneron Pharma | Joseph Goldstein L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 2,707 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Goldstein Joseph L. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,607 | 1,607 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Goldstein L. Joseph | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 135 | 6,382 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 3,613 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 800.00 per share. | 06 Feb 2023 | 3,613 | 6,247 (0%) | 0% | 800 | 2,890,400 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 482.68 per share. | 06 Feb 2023 | 3,613 | 9,860 (0%) | 0% | 482.7 | 1,743,923 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,929 | 1,929 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 165 | 6,247 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 374.12 per share. | 30 Mar 2022 | 2,431 | 8,513 (0%) | 0% | 374.1 | 909,486 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2022 | 2,431 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 700.00 per share. | 30 Mar 2022 | 2,431 | 6,082 (0%) | 0% | 700 | 1,701,700 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,707 | 2,707 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 191 | 6,082 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 650.00 per share. | 10 Sep 2021 | 2,479 | 5,891 (0%) | 0% | 650 | 1,611,350 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 2,479 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 380.95 per share. | 10 Sep 2021 | 2,479 | 8,370 (0%) | 0% | 380.9 | 944,375 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 1,930 | 2,431 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 374.12 per share. | 07 Jun 2021 | 1,930 | 7,821 (0%) | 0% | 374.1 | 722,052 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 525.00 per share. | 07 Jun 2021 | 1,930 | 5,891 (0%) | 0% | 525 | 1,013,250 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 3,613 | 3,613 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 248 | 5,891 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 600.00 per share. | 05 Oct 2020 | 9,212 | 5,643 (0%) | 0% | 600 | 5,527,200 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2020 | 9,212 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 520.01 per share. | 05 Oct 2020 | 9,212 | 14,855 (0%) | 0% | 520.0 | 4,790,332 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2020 | 7,830 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 376.69 per share. | 21 Sep 2020 | 7,830 | 22,217 (0%) | 0% | 376.7 | 2,949,483 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2020 | 4,960 | 2,479 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 380.95 per share. | 21 Sep 2020 | 4,960 | 14,387 (0%) | 0% | 381.0 | 1,889,512 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2020 | 3,784 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 371.40 per share. | 21 Sep 2020 | 3,784 | 9,427 (0%) | 0% | 371.4 | 1,405,378 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 548.13 per share. | 21 Sep 2020 | 3,654 | 15,407 (0%) | 0% | 548.1 | 2,002,867 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 549.07 per share. | 21 Sep 2020 | 2,600 | 12,807 (0%) | 0% | 549.1 | 1,427,582 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 550.11 per share. | 21 Sep 2020 | 1,600 | 11,207 (0%) | 0% | 550.1 | 880,176 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 555.74 per share. | 21 Sep 2020 | 1,530 | 5,663 (0%) | 0% | 555.7 | 850,282 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 551.09 per share. | 21 Sep 2020 | 1,501 | 9,706 (0%) | 0% | 551.1 | 827,186 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 547.28 per share. | 21 Sep 2020 | 1,356 | 19,061 (0%) | 0% | 547.3 | 742,112 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 553.17 per share. | 21 Sep 2020 | 1,101 | 8,092 (0%) | 0% | 553.2 | 609,040 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 554.82 per share. | 21 Sep 2020 | 899 | 7,193 (0%) | 0% | 554.8 | 498,783 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 546.01 per share. | 21 Sep 2020 | 800 | 20,417 (0%) | 0% | 546.0 | 436,808 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 544.96 per share. | 21 Sep 2020 | 700 | 21,217 (0%) | 0% | 545.0 | 381,472 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 552.01 per share. | 21 Sep 2020 | 513 | 9,193 (0%) | 0% | 552.0 | 283,181 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 543.19 per share. | 21 Sep 2020 | 300 | 21,917 (0%) | 0% | 543.2 | 162,957 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 552.35 per share. | 21 Sep 2020 | 20 | 5,643 (0%) | 0% | 552.4 | 11,047 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 617.18 per share. | 21 Aug 2020 | 1,000 | 5,643 (0%) | 0% | 617.2 | 617,180 | Common Stock |